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The promoters of all class II major histocompatibility (MHC) genes contain a positive regulatory motif, the
X element. The DNA-binding proteins specific for this element are presumed to play a critical role in gene
expression, although there is a paucity of functional studies supporting this role. In this study, the X-box-
binding proteins of HLA-DRA were affinity purified from HeLa nuclear extracts. Fractions 46 to 48 contained
an X-box-binding activity and were determined by electrophoretic mobility shift assays to be specific for the X1
element. This X1 sequence-binding-protein, transcriptional activator X1 (TRAX1), was shown to be a specific
transcriptional activator of the HLA-DRA promoter in an in vitro transcription assay. By UV cross-linking
analysis, the approximate molecular mass of TRAX1 including the bound DNA was determined to be 40 kDa.
When the TRAX1 complex was incubated with antibodies against a known recombinant X-box-binding protein,
RFX1, and tested in electrophoretic mobility shift assays, TRAX1 was neither shifted nor blocked by the
antibody. Further analysis with methylation interference showed that TRAX1 bound to the 5* end of the X1
sequence at 2109 and 2108 and created hypersensitive sites at 2114, 2113, and 297. This methylation
interference pattern is distinct from those of the known X1-binding proteins RFX1, RFX, NF-Xc, and NF-X.
Taken together, our results indicate that TRAX1 is a novel X1-sequence-binding protein and transcription
activator of HLA-DRA.
Major histocompatibility complex (MHC) class II molecules
are transmembrane glycoproteins expressed on the cell surface
as heterodimers of noncovalently associated A and B chains (9,
24, 58) and play important roles in immune function (reviewed
in references 17 and 46). These molecules are involved in (i)
the acquisition of the mature T-cell repertoire through positive
and negative selection in the thymus (7, 34), (ii) the induction
of lymphocyte and macrophage/monocyte activation and dif-
ferentiation (6, 12), and (iii) the presentation of processed
antigens to CD4-positive T lymphocytes (31). During an im-
mune response, extracellular antigens are internalized by an-
tigen-presenting cells and are processed and bound by class II
MHC molecules as peptides (25). The peptide-bound class II
molecules are then recognized by complementary T-cell recep-
tors (10). The affinity between the T-cell receptor and a pep-
tide-bound class II molecule is further enhanced by CD4 bind-
ing to a class II MHC molecule, which eventually results in the
transduction of signals leading to T-cell activation and prolif-
eration. Therefore, the regulation of MHC class II expression
affects the extent of T-cell activation and the immune response.
In humans, class II MHC molecules are encoded by MHC
class II genes (HLA-DR, -DP, and -DQ), and their expression
is tissue restricted (reviewed in references 3, 5, and 23). They
are constitutively expressed at high levels by B lymphocytes
and dendritic cells but not by resting T lymphocytes, most
peritoneal macrophages, and nonlymphoid cells (15). How-
ever, MHC class II molecules can be induced on T lympho-
cytes, macrophages, and nonlymphoid cells by a variety of
different external stimuli; among these, gamma interferon
(IFN-g) is one of the most potent regulators of the class II
MHC genes. These complex patterns of class II MHC gene
expression have led to the intense investigation of cis-acting
elements and trans-acting factors that are required for proper
expression of the class II MHC genes (reviewed in references
14, 23, 68, and 70).
Sequence comparisons of the MHC class II promoters have
revealed two highly conserved cis sequence motifs, the X and
Y boxes, in all murine and human class II promoters (5, 38).
Both the X and Y boxes are positive regulators of class II
MHC gene expression and are required for accurate and effi-
cient class II MHC gene expression (20, 60, 61, 70, 75). A
critical role of the X-box-binding proteins for class II MHC
expression has been demonstrated by in vivo footprinting (73),
mutagenesis, and transient chloramphenicol acetyltransferase
(CAT) expression analyses (4, 48, 62). In addition, a subset of
patients with bare lymphocyte syndrome, a class II-negative
hereditary immunodeficiency disease, exhibits a potential reg-
ulatory defect associated with the X1-sequence-binding pro-
tein, RFX (56).
By convention, the X box is subdivided into two target se-
quences, X1 and X2, which interact with several known pro-
teins, including RFX (26, 28), RFX1 (29), NF-X (41, 43),
NF-Xc (11), hXBP-1 (44, 45), X2BP (26), Jun/Fos (2), NF-S
(40), YB-1 (18), and NF-X3/BCF-1 (72). RFX, RFX1, NF-X,
and NF-Xc bind to the X1 sequence of the DRA promoter and
have identical guanine and adenine methylation interference
patterns. RFX is missing in class II-negative bare lymphocyte
syndrome cell lines, but RFX1, NF-X, and NF-Xc are found in
these extracts. It appears that RFX, RFX1, NF-X, and NF-Xc
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are closely related in terms of binding specificity, and most
likely RFX1, NF-X, and NF-Xc are the same as determined by
proteolytic digestion (27). hXBP-1, X2BP, Jun/Fos, and NF-S
bind to the X2 sequence, which is similar to the tetradecanoyl
phorbol acetate-responsive element and the cyclic AMP re-
sponse element (16, 74). hXBP-1 is a bZIP protein which binds
to the DRA promoter but not to the DRB, DQA, or DQB
promoter and can form a heterodimer with c-Fos (but not with
c-Jun) via the leucine zipper motif (49, 50). On the other hand,
X2BP binds to the DRB and DRA promoters with a high
affinity and does not heterodimerize with c-Fos. Jun and Fos
are bZIP family proteins, and a Jun/Fos heterodimer binds to
the X2 sequence of the DRA promoter. NF-S binds to the
DQA and DPA promoters but weakly to the DRA promoter.
YB-1 preferentially binds to the antisense strand of the X2
sequence of DRA (unpublished data) and is a negative regu-
lator of DRA expression (14, 68, 69). NF-X3/BCF-1 is a B-cell-
specific factor which binds to the X3 sequence (59CAGATG39,
located from 2100 to 295) of the DRA promoter and appears
to be related to the helix-loop-helix proteins E12 and E47.
Although a large number of X-box-binding proteins have
been characterized by DNA-binding analyses and lgt11 ex-
pression cloning, the functional significance of most X-box-
binding proteins in class II MHC gene expression is not clear.
To directly examine the functional roles of these X proteins in
class II MHC gene expression, we sought to isolate X-box-
specific transcription factors from crude nuclear extracts by
using a combination of nonspecific and specific affinity col-
umns. Here we describe the isolation of an X1-sequence-bind-
ing protein, transcriptional activator X1 (TRAX1), from HeLa
nuclear extracts. We present evidence showing that TRAX1 (i)
is a transcriptional activator as determined by in vitro tran-
scription; (ii) has an approximate molecular mass of 40 kDa as
determined by UV cross-linking; and (iii) specifically binds to
the X1 sequence of DRA but is distinct from RFX1 as deter-
mined by antibody reactivity and from other known X1 pro-
teins as determined by electrophoretic mobility shift assay
(EMSA) and methylation interference. We also discuss the
implications of how a ubiquitously expressed protein may reg-
ulate tissue-specific or inducible class II MHC gene expression.
MATERIALS AND METHODS
Cells and nuclear extracts. Namalwa B-lymphoblastoid cells (from R. Roeder,
Rockefeller University) and Raji cells (human Epstein-Barr virus-positive Bur-
kitt’s lymphoma cell line) were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum and 1% glutamine. HeLa (human cervical carcinoma
cells) were cultured in suspension-minimum essential medium (S-MEM) sup-
plemented with 5% horse serum, 5% fetal calf serum, and 1% glutamine.
Namalwa, Raji, and HeLa cells were used to prepare nuclear extracts, using a
modification of Dignam’s procedure as previously described (19, 66). Protein
concentrations were determined by the Bio-Rad protein assay, and the extracts
were frozen in aliquots at 708C.
EMSAs and UV cross-linking. The X box and Y box of the DRA promoter
were used as probes in mobility shift assays by the method described previously
(28, 53). Four to 10 mg of nuclear extract was incubated with 2 mg of poly(dI-
dC) z poly(dI-dC) and 50,000 to 100,000 cpm of 32P-end-labeled DNA probes in
a 20-ml reaction volume. After incubation for 20 min at room temperature, the
complexes were resolved at room temperature on a 6% nondenaturing polyacryl-
amide gel containing 13 Tris-glycine. With affinity-purified protein, 5 ml of
affinity-purified TRAX1 and 0.5 mg of poly(dI-dC) z poly(dI-dC) were added in
the 20-ml reaction volume, the reaction mixture was incubated on ice for 30 min,
and the TRAX1 complex was resolved at 48C.
For EMSAs with anti-RFX1 antibody, the antibody was preincubated with
TRAX1 or in vitro-transcribed and -translated RFX1 on ice for 1 h. The reaction
mix was then processed according to the standard procedure with 20 min of
incubation at room temperature before the complexes were resolved on the gel.
For UV cross-linking, the standard EMSA was scaled up 2.5-fold and bro-
modeoxyuridine-substituted 45-bp X1X2 oligonucleotides were used as probes.
After a 20-min incubation, the reaction mixture was irradiated for 30 min in a
cold room. To that mixture, 1 U of micrococcal nuclease (MNase), 4 mg of
DNase I, and 1 ml of 0.5 M CaCl2 were added, and the mixture was incubated at
378C for 30 min. The mixture was then boiled at 95 to 1008C for 5 min and loaded
onto a sodium dodecyl sulfate (SDS)–10% polyacrylamide gel to identify the
molecular weight of the cross-linked TRAX1.
Affinity purification of TRAX1. HeLa nuclear extracts were first chromato-
graphed over a heparin-agarose (Sigma) column. The X-box-binding activity,
monitored by EMSAs with X1X2 radiolabeled probes, was eluted with a linear
gradient from 100 to 1,000 mM KCl in buffer containing 25 mM Tris-HCl (pH
8.0), 20% (vol/vol) glycerol, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, and 0.2 mM EDTA. Fractions were dialyzed against the same buffer
containing 100 mM KCl. Fractions containing the X-box-binding activity were
then chromatographed twice over an X1X2-specific affinity column prepared as
described previously (30, 32, 75), using the 45-bp X1X2 oligonucleotides of the
DRA promoter (Fig. 1). The X-box-binding activity was eluted with a linear
gradient of 100 mM to 2MKCl in the same buffer containing 0.1% Nonidet P-40.
Bovine serum albumin (BSA) (0.3 mg/ml) was added to each fraction before the
dialysis. Fractions were dialyzed against buffer containing 100 mM KCl and 0.1%
Nonidet P-40, and fractions containing the X-box-binding activity determined by
EMSAs were stored at 2708C.
Methylation interference assays. The methylation interference assay was per-
formed as described previously (47, 59, 63), with a minor modification. Briefly,
each strand of the 45-bp oligonucleotides spanning the X1 and X2 sequences of
DRA was separately labeled with [g-32P]ATP at one end with T4 polynucleotide
kinase (New England BioLabs). The labeled strand was then annealed to its
complementary unlabeled strand and filled in with Sequenase (United States
Biochemical). The labeled sense-strand probes were methylated with dimethyl
sulfate for 1 min 10 s, and the labeled antisense-strand probes were methylated
for 1.5 min at room temperature. The standard EMSA reactions were scaled up
10- to 12-fold for each strand, using 105 cpm of the methylated probes per
reaction. The mobility shift reactions were resolved, and bound and free DNAs
were excised from the gel. The bound and free DNAs were recovered by an
Elutrap (Schleicher & Schuell) at 150 V for 2 h and purified by extraction with
phenol-chloroform and then precipitation with 1/3 volume of 7.5 M ammonium
acetate and 4 volumes of 100% ethanol. The bound and free DNAs were then
cleaved with piperidine, and the products of the piperidine cleavage reactions
were analyzed on a 12% polyacrylamide–8 M urea sequencing gel.
In vitro transcription. The standard transcription reaction was performed as
described previously (66, 75), using 10 ml of Namalwa nuclear extract and 59D-
56SXY (4, 71) as a DNA template. 59D-56SXY contains 141 bp of the DRA
promoter linked to the CAT reporter gene, and NcoI-linearized 59D-56SXY
produces a 595-nucleotide (nt) CAT transcript in an in vitro transcription assay.
A radiolabeled 494-nt Sp6 transcript (supplied by R. Kole, University of North
Carolina) was added to each transcription reaction as an internal standard for
sample recovery. To initiate the reconstitution reaction, Namalwa nuclear extract
was first preincubated with cold 45-bp X1X2 oligonucleotides for 5 min at room
temperature to absorb the X-binding proteins and thus to reduce the DRA
X-dependent transcripts (75, 76). Transcription reactions were then reconsti-
tuted by adding affinity-enriched TRAX1. In another group of reconstitution
experiments, competitive oligonucleotides were not added; instead, TRAX1 was
directly added to an in vitro transcription reaction, and its capacity to enhance
transcription was measured. In this protocol, the transcriptional cocktail con-
tained 7 ml of nuclear extract which was determined by titration to produce a
detectable but lowered level of 32P-labeled transcripts. This lowered level of
transcription was essential to detect the reconstituting activity of TRAX1. All
reconstituted transcription reactions were performed in the same salt concen-
tration containing 0.3 mg of BSA per ml to ensure that any difference observed
was due to the reconstitution of the X-dependent activity alone. The final prod-
ucts were visualized by autoradiography.
RESULTS
The X-box-binding activities of HeLa and Raji nuclear ex-
tracts. The X-box-binding activities of crude nuclear extracts
FIG. 1. Oligonucleotide map. Nucleotides are numbered relative to the cap
site. The cis-acting X1, X2, and Y boxes are indicated. X1X2 represents the
wild-type X sequence. The oligonucleotide with mutations in the X1 sequence is
referred to as X1M, and that with mutations in the X2 sequence is designated
X2M. The mutated nucleotides in the X1 and X2 sequences are in the shaded
boxes.
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from HeLa and Raji cells were examined by EMSA with ra-
diolabeled oligonucleotide probes consisting of wild-type
X1X2, X1M (with mutations in the X1 sequence of the
HLA-DR promoter), or X2M (with mutations in the X2 se-
quence of the HLA-DRA promoter) (Fig. 1). Figure 2 shows
EMSA patterns that are nearly identical between Raji and
HeLa extracts. There are several noticeable complexes which
appear to be sensitive to both the X1 and X2 mutations (ar-
rows) and one unique complex which is sensitive only to the X1
mutations and is present in both HeLa and Raji cells (asterisk).
The sensitivity to both X1 and X2 mutations may be explained
by the formation of complexes that require both X1 and X2.
The requirement for both X1 and X2 in some complexes may
be explained by cooperativity or mutual stabilization of some
X1- and X2-binding proteins. Indeed, such a mutual depen-
dency has been observed in an in vivo footprint and in vitro gel
shift analyses wherein a mutation of X1 produced a diminution
of binding at X2, and vice versa (55, 73). In lanes 2, 3, 5, and
6, there are a few complexes that are unique to the mutant
probes and may be caused by the inadvertent generation of
new binding sites.
Affinity purification of the X-box-binding proteins from
HeLa nuclear extracts. HeLa nuclear extracts were chromato-
graphed once through a heparin-agarose column and twice
through an X1X2 affinity column to isolate the X-box-binding
proteins. EMSAs were performed at each purification step to
trace the X-specific activities in fractions. Figure 3A shows
such an EMSA with twice-affinity-enriched fractions 45 to 51
out of 100 fractions collected. The addition of the 45-bp X1X2
oligonucleotide competitors resulted in the complete disap-
pearance of the complex in fractions 46, 47, and 48 (compare
lanes 3 and 4, 5 and 6, and 7 and 8). This result indicated that
fractions 46 to 48 contained X-box-binding proteins. Conse-
quently, fractions 46 to 48 were electrophoresed side by side
with crude HeLa nuclear extracts (Fig. 3B). The affinity-en-
riched proteins in fractions 46 to 48 formed a complex that
comigrated with the X1-sequence-specific proteins found in
HeLa and Raji nuclear extracts (compare with Fig. 2). The fold
enrichment of fractions 46 to 48 was further calculated. Frac-
tions 46 to 48 were enriched 1.3 3 104-fold, with an increase in
the specific activity from 9.75 3 101 (in crude nuclear extract)
to 1.293 106 (in the enriched fractions 46 to 48) densitometric
units of bound DNA per mg of protein.
Fractions 46 to 48 contain an X1-specific DNA-binding pro-
tein. Fractions 46 to 48 were further analyzed in EMSAs using
various labeled oligonucleotides containing mutations in either
FIG. 2. Raji and HeLa extracts exhibit nearly identical EMSA patterns for
the X-box-binding activities. Nuclear extracts were prepared from Raji and HeLa
cells. The binding reaction mixture contained 12% glycerol, 12 mM N-2-hydroxy-
ethylpiperazine-N9-2-ethanesulfonic acid (HEPES)-KOH (pH 7.9), 60 mM
MgCl2, 0.12 mM EDTA, 0.3 mM phenylmethylsulfonyl fluoride, 0.3 mM dithio-
threitol, 2 mg of poly(dI-dC) z poly(dI-dC), 4 to 8 mg of nuclear extract protein,
and 105 cpm of labeled probe in a total volume of 20 ml. Eight micrograms of
nuclear extract protein was used in lanes 1, 2, 4, and 5, and 4 mg of nuclear extract
protein was used in lanes 3 and 6. Probes used were X1X2 (lanes 1 and 4), X1M
(lanes 2 and 5), and X2M (lanes 3 and 6). The positions of the X1- and
X2-sequence-binding activities are indicated by arrows, and that of the X1
sequence binding activity is indicated by an asterisk. F, free probe.
FIG. 3. Purification of DRA X-binding-protein, using an X-specific DNA
affinity column. Crude HeLa nuclear extract was fractionated once on a heparin-
agarose column and twice on an X1X2 DNA affinity column. At each step of
purification, every third fraction was analyzed with 32P-labeled X1X2 probe in
EMSA. Fractions which contained the X-box-binding activity were then pooled
and applied to the next column. (A) DRA X-box-binding activities in fractions
(Frac) 46 to 48. Twice-X-affinity-purified proteins were analyzed in EMSA using
32P-labeled X1X2 probe in the presence (1) or absence (2) of X1X2 cold
competitor (comp.). Only the representative fractions from 45 to 51 out of 100
fractions collected are shown. The arrow indicates the X-specific complex. (B)
Fractions 46 to 48 comigrate with the X1-sequence-specific protein in HeLa
nuclear extract. HeLa nuclear extract (lanes 1 and 2) and fractions 46 to 48 (lanes
3 and 4) were run side by side to locate the corresponding complex in the HeLa
nuclear extract. For an easy comparison with Fig. 2, the corresponding arrows
and asterisk were placed on the left to mark the same complexes in both figures.
F, free probes.
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X1 or X2 to confirm the specificity (Fig. 4A). Fractions 46 to 48
bind to X1X2 and X2M 32P-labeled probes (lanes 1 and 3) but
not to X1M and unrelated DRA-Y 32P-labeled probes (lanes 2
and 4). This finding demonstrates that the proteins in fractions
46 to 48 specifically recognize the wild-type X1 sequence but
not the X2 or Y sequence of HLA-DRA. To evaluate the
possibility that these fractions contain additional DNA-binding
proteins that are blocked by the higher concentration (500 ng)
of nonspecific competitor [poly(dI-dC z poly(dI-dC)] used for
Fig. 4A, the experiment was repeated in the absence of or with
1/10 the concentration of poly(dI-dC) z poly(dI-dC). As seen in
Fig. 4B, the pattern of the EMSA remains unchanged at this
lower concentration of nonspecific competitor, demonstrating
that the X1-box-specific proteins are the predominant binding
activity in these fractions.
We have observed that fractions 46 to 48 formed either a
single broad band (Fig. 3) or two sharp bands (Fig. 4) with the
X1X2 probe in different experiments. Since the molecular
weights of two forms were indistinguishable as determined by
UV cross-linking analysis (unpublished observations), we be-
lieve these two forms may be different conformations or mod-
ifications of the same protein.
Fractions 46 to 48 contain an in vitro transcriptional acti-
vator of the DRA promoter. Several experiments were per-
formed to determine if fractions 46 to 48 contain a transcrip-
tional activator of the DRA promoter. In the first approach,
fractions 46 to 48 were used to reconstitute a transcriptional
extract that was functionally depleted of X-binding proteins.
Namalwa nuclear extracts were used to supply necessary fac-
tors for transcription from the DRA promoter in vitro. The
template plasmid, 59D-56SXY (Fig. 5A), which contained 141
bp of the DRA promoter fused to the CAT gene, was predi-
gested with NcoI to yield a 595-base known transcript in this in
vitro transcription extract. To test the capacity of fractions 46
to 48 to reconstitute the transcriptional activity of DRA, in
vitro transcription assays were performed in the presence of an
excess of cold X1X2 oligonucleotides to functionally deplete
the X-box-binding proteins in crude nuclear extracts. The
amount of X1X2 oligonucleotide competitor was first titrated
to achieve a significant but suboptimal level of competition
(Fig. 5B); this suboptimal level of competition was necessary to
ensure that both a negative and a positive effect of the proteins
in fractions 46 to 48 can be detected in transcription assays.
The X1X2 competitor is specific for the DRA promoter since
it did not reduce the transcription of a dihydrofolate reductase
(DHFR) promoter (data not shown).
Figure 5C shows the reconstitution of DRA transcription
with fractions 46 to 48. In the presence of X1X2 oligonucleo-
tides, the level of the 595-base DRA transcripts was reduced by
approximately two-thirds (compare lanes 1 and 3). However,
this reduction was not observed by an equivalent molar of an
irrelevant competitor, the EL3noSP1 oligonucleotide (lane 2).
When 5 ml of fractions 46 to 48 was added to the reaction,
transcriptional activity of the DRA promoter was restored to
its original level (lane 4), demonstrating that fractions 46 to 48
may contain a transcriptional activator.
The use of DNA competitors in the assay shown in Fig. 5C
raises the criticism that fractions 46 to 48 may displace other
DRA trans-activating factors from the competitor DNA such
that the activation is indirect and due to a sequestration of
competitor DNA. To address this possibility and to further
evaluate the transcriptional activity and specificity of fractions
46 to 48, fractions 46 to 48 were directly added to a transcrip-
tional cocktail containing 7 ml of Namalwa nuclear extract in
the absence of the cold competitors (Fig. 5D). Results in Fig.
5D show that the addition of fractions 46 to 48 enhanced the
DRA-specific 595-base transcripts (compare lanes 1 and 2),
indicating that fractions 46 to 48 directly enhanced DRA tran-
scription. As a specificity control, fractions 46 to 48 were also
added to a reaction containing the DHFR promoter. The
DHFR promoter has two start sites (66), and the products
from these start sites, 976- and 1,016-base transcripts, were
relatively unaffected by these fractions (compare lanes 3 and
4). It is important to note that Fig. 5D was exposed for a
shorter time (one-third as long as Fig. 5C) to best demonstrate
the clear differences in the enhancement between the DHFR-
and DRA-specific transcripts. The 494-base (internal stan-
dard) and 595-base DRA-specific transcripts in Fig. 5D appear
lighter than those in Fig. 5C because of this short exposure. To
quantitate the results, a densitometric tracing of the DRA- or
DHFR-specific transcript was normalized to the densitometric
reading of the internal standard, the 494-base transcript in the
same lane. Such an analysis shows that the DRA-specific tran-
script was enhanced approximately fivefold over the DHFR
transcript. Therefore, fractions 46 to 48 contain the transcrip-
tion activator with specificity for the DRA promoter. This
transcription activator will be referred to as TRAX1.
TRAX1 is a unique X1-sequence-binding protein. To date,
recombinant RFX (RFX1) is the only cloned X1-binding pro-
tein. An antiserum raised against recombinant RFX1 specifi-
cally immunoprecipitated a 116-kDa protein as well as the
140-kDa protein corresponding to RFX1 (29). A crucial issue
is whether TRAX1 is RFX1. Affinity-enriched TRAX1 and the
in vitro-translated RFX1 were preincubated with preimmune
and anti-RFX1 immune sera in an EMSA (Fig. 6A). The
complex formed with recombinant RFX1 was completely
blocked by the anti-RFX1 antibody (compare lanes 4 and 5). In
contrast, the anti-RFX1 antibody did not block or supershift
TRAX1 (compare lanes 6 and 7), suggesting that TRAX1 is
not related to RFX1.
The molecular weight of TRAX1 was estimated by UV
cross-linking analysis (Fig. 6B). In the absence of nuclease
treatment, a number of higher-molecular-weight complexes
FIG. 4. Fractions 46 to 48 contain an X1-binding protein. (A) Fractions 46 to
48 were analyzed in EMSA using 32P-labeled X1X2, X1M, X2M, and DRA-Y
probes in parallel. Fractions (Fr) 46 to 48 are sensitive to mutations in the X1
sequence (lane 2) but not to the X2 sequence (lane 3) and do not bind to an
unrelated Y sequence (lane 4). To increase the resolution of the X-specific
complexes (arrows), DRA-Y free probe was electrophoresed off the gel. (B)
Fractions 46 to 48 were analyzed in the absence or in the presence of 10-fold-less
poly(dI-dC) z poly(dI-dC).
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were observed in crude HeLa extract and TRAX1 (lanes 3 and
5). In the presence of both DNase and MNase, a major band
of approximately 40 kDa appeared in crude HeLa extract as
well as in TRAX1 (lanes 4 and 6). This size estimation includes
protein and bound oligonucleotide that remained after nucle-
ase treatment. The 40-kDa complex was efficiently abolished
by a cold competitor that contained an intact X1 sequence
(lane 7) but not one that contained a mutated X1 sequence
(lane 8).
Another confirmation that TRAX1 is distinct from RFX1 or
other known X1-sequence-binding proteins was derived from
methylation interference analysis. This analysis was performed
to identify the protected contact points involved in the forma-
tion of the TRAX1 complex (Fig. 7). Methylation at guanine
residues and to a lesser extent adenine residues interferes with
protein binding, and the band intensity is underrepresented in
the population of the bound DNA and overrepresented in the
population of free DNA. In agreement with the results of the
gel mobility shift using X1M probes shown in Fig. 4, partial
interference is located at 2109 and 2108 on the antisense
strand and is absent on the sense strand. In addition, hyper-
sensitive sites are observed at 2114, 2113, and 297 on the
antisense strand. These hypersensitivity sites may be generated
by an increased accessibility of dimethyl sulfate to the minor
groove of DNA or local distortion in the three-dimensional
structure of DNA around this region. This methylation inter-
ference profile of TRAX1 is different from previously pub-
lished patterns for RFX, RFX1, NF-X, and NF-Xc. Together,
these data indicate that TRAX1 is an X1-sequence-binding
protein which has not been characterized previously.
DISCUSSION
Characterization of TRAX1. Using a combination of non-
specific and specific affinity columns, we have enriched
TRAX1, a novel X1-sequence-binding protein, from HeLa
nuclear extracts (Fig. 3 and 4). To determine its functional role
in class II MHC gene regulation, TRAX1 was examined in an
in vitro transcription assay and was determined to be a positive
trans-acting factor of the DRA promoter (Fig. 5C and D).
Analysis of TRAX1 by UV cross-linking showed that the mo-
lecular mass of TRAX1 is approximately 40 kDa (Fig. 6B).
TRAX1 is distinct from RFX1, since an antiserum raised
against recombinant RFX1 failed to block or supershift
TRAX1 (Fig. 6A). In addition, the methylation interference
pattern of TRAX1 is distinct from those of other known X1-
sequence-binding proteins. TRAX1 interacts at the 59 end of
the X1 sequence (Fig. 7), and this methylation interference
result is consistent with the specificity determined by EMSA
(Fig. 4). Together, our findings indicate that TRAX1 is a novel
X1-sequence-binding protein. This observation does not, how-
ever, exclude the possibility that TRAX1 is a subunit of RFX
or other X-box-binding proteins.
The possible role of TRAX1 in HeLa cells.HeLa cells do not
normally express class II molecules unless stimulated with cy-
tokines such as IFN-g (37), yet a DRA-specific transcriptional
FIG. 5. Fractions 46 to 48 contain a DRA-specific transcriptional activator,
TRAX1. (A) Map of DNA template 59D-56SXY plasmid used in an in vitro
transcription assay. 59D-56SXY contains 141 bp of the DRA promoter including
the TATA (T), octamer (O), Y, X, and W boxes cloned in front of the CAT gene
of parent plasmid pD164-2 (4). b, base. (B) Titration of X1X2 cold competitors.
Increasing amounts of double-stranded 45-bp X1X2 oligonucleotides (30- to
70-fold molar excess) were added to an in vitro transcription assay containing the
template, 59D-56SXY (see Materials and Methods). The upper arrow indicates a
595-base transcript initiated from the correct DRA transcriptional start site. This
595-base transcript was decreased by X1X2 cold competitors relative to an
internal standard 494-base transcript (lower arrow). Lane 1, no competitor; lanes
2 to 6, reactions performed in the presence of 30, 40, 50, 60, and 70 molar
excesses of cold 45-bp X1X2 oligonucleotides, respectively. (C) Fractions 46 to
48 reconstituted the transcriptional activity of DRA. Transcription reactions
were supplemented with either 5 ml of the affinity column buffer containing 100
mM KCl plus 0.3 mg of BSA per ml (2) or fractions (Frac) 46 to 48 (1). The
level of a DRA-dependent 595-base transcript (upper arrow) in each reaction
was compared with the level of an internal standard 494-base transcript (lower
arrow). Lane 1, no cold competitor was added; lane 2, a 50-fold molar excess of
an irrelevant cold competitor oligonucleotide, ELSnoSp1, was added as a spec-
ificity control; lane 3, a 50-fold molar excess of X1X2 cold competitor was added
to reduce the level of the 595-base transcripts; lane 4, a 50-fold molar excess of
X1X2 cold competitor and 5 ml of fractions 46 to 48 were added to reconstitute
the 595-base DRA-specific transcripts. The asterisks in panels B and C indicate
an aberrant transcript that resulted from the depletion of factors with cold 45-bp
X1X2 competitors. (D) Fractions 46 to 48 contained a DRA-specific transcrip-
tional activator. In vitro transcription assays (see Materials and Methods) were
performed in the absence of X1X2 cold competitor to detect the enhancement
of DRA transcription by fractions 46 to 48. Under this condition, the DHFR- and
DRA-driven templates were tested in the absence (lanes 1 and 3) and presence
(lanes 2 and 4) of fractions 46 to 48. The DHFR template was prepared by
predigesting plasmid DHFR-239 with ScaI to produce 976- and 1,016-base tran-
scripts (66). Densitometric tracings of the DRA- and DHFR-specific transcripts
(arrows) were performed by NIH Image 1.47, and the results were normalized to
the densitometric reading of the internal standard, the 494-base radiolabeled
RNA. Txc, specific transcripts either from the DHFR (control)- or DRA (595-
base)-specific template.
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activator, TRAX1, was affinity enriched from unstimulated
HeLa cells. The in vivo footprinting analyses with IFN-g-stim-
ulated U373-MG (73) and HeLa cells (37) demonstrated that
the X element of DRA was loaded with a protein in unstimu-
lated HeLa cells but the protein loading to the X element
became progressively stronger over time when the cells were
stimulated with IFN-g. These in vivo footprinting data suggest
a model wherein the IFN-g treatment results in a stronger and
productive binding of TRAX1 to the X element, possibly
through the interaction between preexisting TRAX1 and an
IFN-g-induced protein or the release of a repressor such as
YB-1 or both (69). The formation of this productive interac-
tion thus results in the production of DRA gene expression.
Similarly, the requirement of an additional cellular factor for
the formation of productive E47 and MyoD heterodimeriza-
tion has been reported (67).
Importance of chromatin structure for cell-specific expres-
sion of class II. Although we have performed only limited
analysis of TRAX1, TRAX1 appears to be expressed by cells
that express DRA (Raji and Namalwa) as well as nonexpres-
sors such as unstimulated HeLa cells. Most of the other X- and
Y-element-binding proteins which have been described so far
are ubiquitously expressed in cells as well. While the search for
factors which may explain the tissue specificity of class II MHC
gene expression has not revealed many such factors, there are
two lines of evidence which may explain how ubiquitously
expressed proteins may play a critical role in the proper coor-
dinate regulation and in tissue-specific or inducible expression
of the class II MHC genes. First, in vivo footprinting analysis
shows that in some class II-negative mutant cell lines, the
expression of class II MHC genes may depend on the accessi-
FIG. 6. (A) TRAX1 is not related to RFX1. Tobacco mosaic virus (TMV)
RNA from Ambion Inc. (Austin, Tex.) and in vitro-transcribed RFX1 RNA were
translated in vitro, using a Promega translation system. In vitro-translated pro-
teins were then incubated with an X1X2 oligonucleotide and analyzed by EMSA.
Lane 1, in vitro translation mix with no RNA added; lane 2, in vitro-translated
TMV protein; lane 3, in vitro-translated RFX1; lane 4, in vitro-translated RFX1
incubated with preimmune serum (P); lane 5, in vitro-translated RFX1 incubated
with anti-RFX1 antibody (I); lane 6, TRAX1 incubated with preimmune serum
(P); lane 7, TRAX1 incubated with anti-RFX1 antibody (I). The arrow indicates
the RFX1 complex, and the asterisk indicates the TRAX1 complex. F, free
probes. The two bands below the RFX1 complex were detected in the negative
controls that had H2O or TMV mRNA and are inherent on the in vitro trans-
lation mixture. (B) TRAX1 is approximately 40 kDa. TRAX1 was UV cross-
linked to the bromodeoxyuridine-substituted 32P-labeled X1X2. The complex
was then digested with nucleases, and the molecular weight of TRAX1 was
visualized on an SDS–10% polyacrylamide gel. Lane 1, X1X2 probe subjected to
UV cross-linking without added proteins; lane 2, proteins without UV cross-
linking; lane 3, UV cross-linked crude HeLa nuclear extract; lane 4, UV cross-
linked crude HeLa nuclear extract digested with DNase and MNase; lane 5, UV
cross-linked TRAX1; lane 6, UV cross-linked TRAX1 digested with DNase and
MNase; lane 7, UV cross-linked TRAX1 in the presence of X2M cold competitor
followed by digestion with DNase and MNase; lane 8, UV cross-linked TRAX1
in the presence of X1M cold competitor followed by digestion with DNase and
MNase. Positions of molecular mass markers (in kilodaltons) are at the left; the
estimated molecular mass of TRAX1 is approximately 40 kDa.
FIG. 7. Methylation interference analysis of TRAX1. (A) Methylation inter-
ference profile of TRAX1. Methylated 45-bp X1X2 oligonucleotide was used as
a probe. Bound (B) and free (F) DNAs were separated on a nondenaturing
polyacrylamide gel, isolated, purified, and cleaved with piperidine. The cleaved
DNAs were then analyzed on a 12% sequencing gel. Arrows indicate residues at
which methylation specifically interfered with protein binding; stars indicate
residues which are hypersensitive. (B) Summary of the interference pattern of
TRAX1. The locations of the X1 and X2 sequences, as well as the numbers of
nucleotides relative to the cap site, are indicated. The dots indicate G residues at
which methylation specifically interferes with protein binding, and the stars
indicate residues which are enhanced.
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bility of the promoter by transcription factors. In the DR-
negative Nacera, Ramia, BCH, and 6.6.1 cell lines, the DRA
promoter lacks in vivo protein binding; however, integration of
this promoter in another chromosomal site resulted in altered
accessibility of the promoter and binding of proteins (35, 36).
Second, a significant body of data suggests that chromatin
structure plays an important role in gene activity and that the
presence of core histone octamer and histone H1 can repress
transcription factors from binding to a promoter (1, 21, 22, 39,
42). Combining these observations leads to a model wherein
transcription factors compete with histone molecules for bind-
ing to the class II MHC promoters. The tissue-specific and
coordinate regulation of MHC class II expression may rely on
activators similar to glucocorticoid receptor (8, 51, 52), POH4
and POH2 in yeast cells (57), and GA14-VP16 (33), as a few
examples, which can open the chromatin structure. Once the
chromatin structure is opened by the activators, the class II
transcription factors gain access to the promoters, which re-
sults in the activation of the class II MHC genes. According to
this model, the defect in these DR-negative cell lines may
depend upon activators which can open the chromatin struc-
ture. To test this hypothesis, TRAX1 and/or any other proteins
specific for the class II MHC promoter can be examined to
determine whether they can replace nucleosomes, using an in
vitro transcription assay reconstituted with chromatin tem-
plates which contain physiological spacing of nucleosomes.
The newly described CIITA (MHC class II transactivator)
demonstrates yet another level of control on MHC class II
gene expression (64, 65). CIITA has been shown to fully re-
store HLA class II expression in RJ2.25 and BLS-2 cells with-
out directly binding to DNA. RJ2.25 and BLS-2 are DR-neg-
ative cell lines with normal occupancy of transcription factors
shown by in vivo footprinting. Presently, it is unclear how CIITA
regulates MHC class II gene expression except that CIITA ex-
pression is correlated with and precedes class II MHC gene ex-
pression in IFN-g-treated cells (13, 65). It will be interesting to
test the effect of CIITA in TRAX1-induced class II MHC gene
expression and the interaction between TRAX1 and CIITA.
ACKNOWLEDGMENTS
We thank J. M. Boss for providing critical and valuable discus-
sion and M. F. Criscitiello and K. C. Chin for excellent technical
assistance.
This work was supported by National Institutes of Health grants
CA48185, IA29564, and CA29589 and an American Cancer Society
Faculty Award to J.P.-Y.T. and by an NIH training grant and a Na-
tional Institutes of Health individual postdoctoral fellowship to Y.I.-L.
ADDENDUM
During revision of the manuscript, RFX purified from hu-
man cells was shown by Durand et al. to contain a 36-kDa
DNA-binding subunit (20a).
ADDENDUM IN PROOF
Since the acceptance of the manuscript, another paper on
CIITA and IFN-g induction has been published (C.-H. Chang,
J. D. Fontes, M. Peterlin, and R. A. Flavell, J. Exp. Med.
180:1367–1374, 1994).
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